Abstract: Disclosed is a betacoronavirus fusion recombinant protein, comprising an RBD region and a COVID19-SF5 fragment of a spike protein of SARS-COV-2 (COVID-19), and an amino acid sequence of the COVID19-SF5 fragment is an 880th amino acid to a 1084th amino acid of the S protein of the novel coronavirus COVID-19. According to the invention, a constant conserved fragment (COVID19-SF5) and a receptor binding domain (RBD) fragment are fused and expressed to provide a more-effective constant universal vaccine candidate recombinant fusion protein for such type of coronavirus, thus providing broader and better protection measures from two standpoints of inhibiting receptor recognition and providing universal protection.

Abstract: It relates to a ribonucleic acid aptamer having an inhibitory effect on non-small cell lung cancer and a pharmaceutical composition comprising the same. The ribonucleic acid aptamer can bind to human non-small cell lung cancer in vivo or in vitro with high specificity and high affinity to achieve an effect of inhibiting non-small cell lung cancer; and the ribonucleic acid aptamer can also be linked, coupled or polymerized with other non-small cell lung cancer therapeutic drugs to achieve a more excellent effect of inhibiting non-small cell lung cancer.

Abstract: It relates to a ribonucleic acid aptamer having an inhibitory effect on non-small cell lung cancer and a pharmaceutical composition comprising the same. The ribonucleic acid aptamer can bind to human non-small cell lung cancer in vivo or in vitro with high specificity and high affinity to achieve an effect of inhibiting non-small cell lung cancer; and the ribonucleic acid aptamer can also be linked, coupled or polymerized with other non-small cell lung cancer therapeutic drugs to achieve a more excellent effect of inhibiting non-small cell lung cancer.

Abstract: The release of bradykinin into the circulatory system is potentiated by administration of a polypeptide having an amino acid sequence corresponding to domain 3 of the human kininogen heavy chain. The polypeptide competitively inhibits the binding of high and low molecular weight kininogen to platelets and other cells which protect the kininogens from kallikrein cleavage, thereby increasing the level of bradykinin in the cirulation. The resulting in vivo effect is an intravascular elevation of bradykinin and concomitant lowering of blood pressure. The domain 3 polypeptide also inhibits thrombin-induced platelet and endothelial cell activation.